cyclohexanoic acid N-phenylhydrazide | 488831-75-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cyclohexanoic acid N-phenylhydrazide
• 英文别名: N-phenylcyclohexanecarbohydrazide
• CAS: 488831-75-0
• 化学式: C₁₃H₁₈N₂O
• 分子量: 218.299
• InChiKey: MPAFHIGRAXJLNA-UHFFFAOYSA-N

物化性质

• 沸点：
  353.7±25.0 °C(Predicted)
• 密度：
  1.144±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cyclohexanoic acid N-phenylhydrazide 在 P₂S₅ 作用下， 以 苯 为溶剂， 生成 thiocyclohexanoic acid N-phenylhydrazide
  参考文献：
  名称：

  Synthesis of taxol enhancers

  摘要：

  本发明涉及一种从一个酰肼起始化合物制备硫代酰肼产物化合物的方法。所述酰肼起始化合物由结构式（I）表示：1 所述硫代酰肼产物化合物由结构式（II）表示：2 在结构式（I）-（II）中，R1和R2分别独立地是脂肪基，取代的脂肪基，芳基或取代的芳基，或者R1和R2连同它们连接的碳和氮原子形成一个非芳杂环环，该杂环可以与一个芳环融合。当R2是芳基或取代的芳基时，R5是一个肼保护基；当R2是脂肪基或取代的脂肪基时，R5是-H或肼保护基。R10是-H或取代或未取代的烷基。所述方法包括将起始化合物与硫酰化试剂反应的步骤。

  公开号：

  US20030069225A1
• 作为产物：
  描述：

  苯肼 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 cyclohexanoic acid N-phenylhydrazide
  参考文献：
  名称：

  Syntheses and antitumor activities of N′1,N′3-dialkyl-N′1,N′3-di-(alkylcarbonothioyl) malonohydrazide: The discovery of elesclomol

  摘要：

  A series of N'(1),N'(3)-dialkyl-N'(1),N'(3)-di(alkylcarbonothioyl) malonohydrazides have been designed and synthesized as anticancer agents by targeting oxidative stress and Hsp70 induction. Structure-activity relationship (SAR) studies lead to the discovery of STA-4783 (elesclomol), a novel small molecule that has been evaluated in a number of clinical trials as an anticancer agent in combination with Taxol. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.032

文献信息

• Synthesis of taxol enhancers
  申请人：Shionogi BioResearch Corp.

  公开号：US20030069225A1

  公开（公告）日：2003-04-10

  Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I): 1 The thiohydrazide product compound is represented by Structural Formula (II): 2 In Structural Formulas (I)-(II), R 1 and R 2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R 1 and R 2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R 2 is an aryl group or a substituted aryl group, then R 5 is a hydrazine protecting group; and when R 2 is an aliphatic or substituted aliphatic group, then R 5 is —H or a hydrazine protecting group. R 10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.

  本发明涉及一种从一个酰肼起始化合物制备硫代酰肼产物化合物的方法。所述酰肼起始化合物由结构式（I）表示：1 所述硫代酰肼产物化合物由结构式（II）表示：2 在结构式（I）-（II）中，R1和R2分别独立地是脂肪基，取代的脂肪基，芳基或取代的芳基，或者R1和R2连同它们连接的碳和氮原子形成一个非芳杂环环，该杂环可以与一个芳环融合。当R2是芳基或取代的芳基时，R5是一个肼保护基；当R2是脂肪基或取代的脂肪基时，R5是-H或肼保护基。R10是-H或取代或未取代的烷基。所述方法包括将起始化合物与硫酰化试剂反应的步骤。
• Treatment for cancers
  申请人：Synta Pharmaceuticals Corporation

  公开号：US20040225016A1

  公开（公告）日：2004-11-11

  One embodiment of the present invention is a method of treating a subject with a multi-drug resistant cancer. The method comprises administering to the subject an effective amount of a compound represented by Structural Formula (I): 1 Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group, or, Y, taken together with both>C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. R 1 -R 4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R 1 and R 3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R 2 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Preferably R 1 and R 2 are the same and R 3 and R 4 are the same. R 5 -R 6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. Z is ═O or ═S.

  本发明的一种实施例是一种治疗多药耐药癌症患者的方法。该方法包括向患者施用式(I)所表示的化合物的有效量：其中1Y是共价键或取代或未取代的直链烃基，或Y与其结合的两个>C=Z基团一起形成取代或未取代的芳香族基团。R1-R4独立地为—H、脂肪基、取代脂肪基、芳基或取代芳基，或者R1和R3与它们结合的碳和氮原子以及/或R2和R4与它们结合的碳和氮原子形成一个非芳杂环环，可选地与芳环融合。最好的是R1和R2相同，R3和R4相同。R5-R6独立地为—H、脂肪基、取代脂肪基、芳基或取代芳基。Z为═O或═S。
• Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP2100605A1

  公开（公告）日：2009-09-16

  There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein Y, Z and R1 to R6 have meanings given in the description, for use in the treatment of melanoma or renal cancer by administration of said compound, in the same or separate pharmaceutical composition, with paclitaxel or a paclitaxel analog. There is also provided the use of a compound of formula (I) for the production of a medicament for administration, in the same or separate pharmaceutical composition, with paclitaxel or a paclitaxel analog, for treating melanoma or renal cancer.

  本发明提供了一种式 (I) 的化合物： 或其药学上可接受的盐，其中 Y、Z 和 R1 至 R6 具有描述中给出的含义，用于通过在相同或单独的药物组合物中与紫杉醇或紫杉醇类似物一起施用所述化合物来治疗黑色素瘤或肾癌。还提供了式(I)化合物用于生产治疗黑色素瘤或肾癌的药物，在相同或单独的药物组合物中，与紫杉醇或紫杉醇类似物一起给药。
• TAXOL ENHANCER COMPOUNDS
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP1406870A1

  公开（公告）日：2004-04-14
• SYNTHESIS OF TAXOL ENHANCERS
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP1406868A1

  公开（公告）日：2004-04-14